Oxaliplatin
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2002
- First approval year
- 2002
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Oxaliplatin
- Molecular weight
- 395.27
- Structure (SMILES)
- C1[C@H]([C@H](N)CCC1)N.[O-]C(=O)C(=O)[O-].[Pt+2]
- eloxatin
- Eloxatin
- oxaliplatin
- Oxaliplatin
- oxaliplatin component of folfox
- Oxaliplatin component of folfox
- oxaliplatin component of xelox
- Oxaliplatin component of xelox
- (SP-4-2-(1R-TRANS))-(1,2-CYCLOHEXANEDIAMINE-N,N')(ETHANEDIOATO(2-)-O,O')PLATINUM
- capecitabine oxaliplatin 5 fluorouracil
- Drug: Oxaliplatin
- eloxatin
- folfox component oxaliplatin
- Folfox component oxaliplatin
- jm 83
- JM-83
- l ohp
- L-OHP
- mbp 426 liposomal oxaliplatin
- MBP-426
- MBP-426 (LIPOSOMAL OXALIPLATIN)
- nsc 266046
- NSC-266046
- oxaliplatin
- Oxaliplatin
- OXALIPLATIN
- OXALIPLATIN (205803BIJ)
- Oxaliplatin (Eloxatin)
- Oxaliplatin (Eloxatin®)
- Oxaliplatin (in FOLFOX)
- Oxaliplatin (L-OHP)
- Oxaliplatin (OXAL)
- oxaliplatin (SR96669)
And 51 more, listed on the interactive page.
- ATC classification codes
- L01XA03
Sources for recorded values
- CAS registry numbers
- 61825-94-3
- ChEMBL ID
- CHEMBL414804
- InChIKey
- ZROHGHOFXNOHSO-BNTLRKBRSA-L
- PubChem compound IDs
- 9887054
- RxNorm IDs (RxCUI)
- 32592
- FDA ingredient codes (UNII)
- 04ZR38536J
- Applicant
- SHANDONG
- Approval date
- 15 Jan 2026
- Application number
- ANDA219765
- Patents
- 0
- Designations
- 5
- First in class
- No
- Fast track
- Yes
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- Yes
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- oxaliplatin
- Type
- Synthetic organic
- Drug name stem
- -platin
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
Mechanisms of action
- Mechanism
- DNA inhibitor
- Action type
- Inhibitor
- Target
- DNA
- Condition
- Lymphoma, Follicular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000096
- Subject identifier
- D008224
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000178
- Subject identifier
- D013274
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Hodgkin Disease
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Lymphoma, T-Cell, Peripheral
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000211
- Subject identifier
- D016411
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Adenocarcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000228
- Subject identifier
- D000230
- Condition
- Carcinoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000365
- Subject identifier
- D015179
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000389
- Subject identifier
- D008545
- Condition
- Lymphoma, Large B-Cell, Diffuse
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000403
- Subject identifier
- D016403
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Neoplasms, Germ Cell and Embryonal
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000514
- Subject identifier
- D009373
- Condition
- Leukemia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000565
- Subject identifier
- D007938
- Condition
- Lymphoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000574
- Subject identifier
- D008223
- Condition
- Mesothelioma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000588
- Subject identifier
- D008654
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Neuroblastoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000621
- Subject identifier
- D009447
- Condition
- Carcinoma, Renal Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000681
- Subject identifier
- D002292
- Condition
- Small Cell Lung Carcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000702
- Subject identifier
- D055752
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000707
- Subject identifier
- D002294
- Condition
- Ovarian Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001075
- Subject identifier
- D010051
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002617
- Subject identifier
- D008545
And 79 more, listed on the interactive page.
- Condition identifier
- EFO_0000178
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000182
- Condition identifier
- EFO_0000183
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000228
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000313
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000365
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000403
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000503
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000514
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000574
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000588
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000621
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000638
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000681
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000707
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- EFO_0002618
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002916
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003100
- Condition identifier
- EFO_0003859
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003860
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003869
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003891
- Highest recorded phase
- 3
And 190 more, listed on the interactive page.
Warnings
- Warning
- Black Box Warning
- Effect
- immune system toxicity
Open Targets warnings
- Warning
- Black Box Warning
- Effect
- immune system toxicity
- Country
- United States
- Event
- bone marrow failure
- Reports
- 430
- Reporting signal score
- 484.184
- Event
- chills
- Reports
- 706
- Reporting signal score
- 403.133
- Event
- dermatitis acneiform
- Reports
- 220
- Reporting signal score
- 422.649
- Event
- diarrhoea
- Reports
- 3,036
- Reporting signal score
- 1,374.3
- Event
- disease progression
- Reports
- 1,115
- Reporting signal score
- 1,069.46
- Event
- febrile neutropenia
- Reports
- 706
- Reporting signal score
- 544.347
- Event
- gastrointestinal toxicity
- Reports
- 187
- Reporting signal score
- 361.878
- Event
- haematotoxicity
- Reports
- 282
- Reporting signal score
- 451.318
- Event
- headache
- Reports
- 236
- Reporting signal score
- 355.199
- Event
- laryngospasm
- Reports
- 384
- Reporting signal score
- 1,084.18
- Event
- leukopenia
- Reports
- 690
- Reporting signal score
- 595.873
- Event
- metastases to liver
- Reports
- 274
- Reporting signal score
- 395.296
- Event
- mucosal inflammation
- Reports
- 586
- Reporting signal score
- 754.604
- Event
- myelosuppression
- Reports
- 267
- Reporting signal score
- 375.837
- Event
- nausea
- Reports
- 2,539
- Reporting signal score
- 548.354
- Event
- neuropathy peripheral
- Reports
- 1,988
- Reporting signal score
- 2,909.96
- Event
- neurotoxicity
- Reports
- 765
- Reporting signal score
- 1,464.52
- Event
- neutropenia
- Reports
- 1,912
- Reporting signal score
- 1,853.36
- Event
- palmar-plantar erythrodysaesthesia syndrome
- Reports
- 778
- Reporting signal score
- 1,338.22
- Event
- paraesthesia
- Reports
- 970
- Reporting signal score
- 632.409
- Event
- peripheral sensory neuropathy
- Reports
- 296
- Reporting signal score
- 559.342
- Event
- polyneuropathy
- Reports
- 328
- Reporting signal score
- 495.963
- Event
- portal hypertension
- Reports
- 176
- Reporting signal score
- 376.207
- Event
- pyrexia
- Reports
- 1,517
- Reporting signal score
- 422.968
- Event
- skin toxicity
- Reports
- 254
- Reporting signal score
- 498.654
And 4 more, listed on the interactive page.
- NCT00003260
- NCT00003287
- NCT00003427
- NCT00003594
- NCT00004102
- NCT00004187
- NCT00005050
- NCT00006015
- NCT00006115
- NCT00006468
- NCT00006479
- NCT00008060
- NCT00008281
- NCT00012389
- NCT00016198
- NCT00016978
- NCT00017082
- NCT00025142
- NCT00026299
- NCT00034619
- NCT00039208
- NCT00049101
- NCT00055822
- NCT00058474
- NCT00061815
And 1,306 more, listed on the interactive page.
- Dose
- 85 mg/m 2
- Route
- Intravenous
- How often
- Every 2 weeks
Conditions of use
- Administer over 120 minutes in separate bags with leucovorin
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 15
- Molecular formula
- C8H12N2O4Pt
- Monoisotopic mass
- 397.060151
- Natural product
- No
- 0781-3315
- 0781-3317
- 0781-9315
- 0781-9317
- 16729-332
- 25021-233
- 31722-357
- 31722-358
- 42677-336
- 42677-337
- 43066-014
- 43066-018
- 55150-331
- 55150-332
- 61703-363
- 67457-442
- 67457-469
- 68001-468
- 68083-170
- 68083-171
- 68083-176
- 68083-177
- 68083-314
- 71288-101
- 71288-149
And 15 more, listed on the interactive page.
- Recorded assays
- 32
- Active assays
- 10
Active assay types
- Screening
- Antineoplastic Agents
Related records
Trials (1,697)
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- 1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.
- 2 Versus 6 Hour Oxaliplatin Infusions in Patients With Gastrointestinal Cancers
- 2nd-line Treatment of Metastatic Colorectal Cancer
- 5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
- 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab
- 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
- A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
- A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma
- A Clinical Study of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in the Treatment of Advanced Colorectal Cancer
- A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
- A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
- A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
- A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer
- A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
- A Clinical Trial of Docetaxel and Oxaliplatin in Patients With Recurrent or Metastatic Breast Cancer
- A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric Cancer
- A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer
Approved for (2)
- Cancer
- Neoplasm
In development for (103)
- Acute myeloid leukemia Phase 1
- Adenocarcinoma Phase 3
- Adult glioblastoma Phase 1
- Adult hepatocellular carcinoma Phase 3
- Adult T-cell leukemia/lymphoma Phase 2
- Anus cancer Phase 2
- Bile duct cancer Phase 2
- Bile duct carcinoma Phase 2
- Biliary tract cancer Phase 3
- Biliary tract neoplasm Phase 3
- Breast cancer Phase 2
- Breast neoplasm Phase 2
- Carcinoid tumor Phase 2
- Carcinoma Phase 3
- Carcinoma of esophagus Phase 3
- Central nervous system germ cell tumor Phase 2
- Central nervous system neoplasm Phase 2
- Cervical cancer Phase 2
- Cholangiocarcinoma Phase 3
- Colon adenocarcinoma Phase 3